

**PB 10 of 2024**

National Health (Minimum Stockholding) Amendment Determination (No. 1) 2024

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 30/01/2024

Nikolai Tsyganov

Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments commencing 1 February 2024 2

National Health (Minimum Stockholding) Determination 2023 2

Schedule 2—Amendments commencing 1 June 2024 34

National Health (Minimum Stockholding) Determination 2023 34

1 Name

 (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 1) 2024*.

 (2) This instrument may also be cited as PB 10 of 2024.

2 Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | 1 February 2024. | 1 February 2024 |
| 2. Schedule 1 | 1 February 2024. | 1 February 2024 |
| 3. Schedule 2 | 1 June 2024. | 1 June 2024 |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

 This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

 Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 February 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Aciclovir | Tablet 200 mg | Oral | GenRx Aciclovir | between 1 December 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol | Oral | Fosamax Plus 70 mg/140 mcg | between 1 July 2023 and 31 December 2023—1.5 months stock by reference to usual demand |
| Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol | Oral | Fosamax Plus | between 1 July 2023 and 31 December 2023—1.5 months stock by reference to usual demand |

2 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Allopurinol | Tablet 300 mg | Oral | Allopurinol APOTEX | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |

3 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amisulpride | Tablet 100 mg | Oral | Amisulpride 100 Winthrop | Between 1 October 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 10 mg | Oral | APX‑Amitriptyline | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |

4 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amlodipine | Tablet 10 mg (as besilate) | Oral | Amlodipine Amneal | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Amlodipine | Tablet 5 mg (as besilate) | Oral | Amneal | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |

5 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Amoxyclav AN 500/125 | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Amoxyclav AN 875/125 | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |

6 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Aripiprazole | Tablet 10 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Aripiprazole | Tablet 10 mg | Oral | Aripic Aripiprazole | between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand |

7 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Aripiprazole | Tablet 30 mg | Oral | Aripiprazole generichealth | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |

8 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Atenolol | Tablet 50 mg | Oral | Atenolol Amneal | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |

9 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Atomoxetine | Capsule 80 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Atorvastatin | Tablet 10 mg (as calcium) | Oral | Atorvastatin GH | between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand |

10 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Atorvastatin | Tablet 20 mg (as calcium) | Oral | Atorvastatin GH | Between 1 October 2023 and 29 February 2024—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Atorvastatin | Tablet 40 mg (as calcium) | Oral | Atorvastatin GH | between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand |

11 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Azathioprine | Tablet 50 mg | Oral | Azathioprine GH | Between 1 October 2023 and 31 January 2024—0 months stock by reference to usual demand |

12 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Bleomycin | Powder for injection containing bleomycin sulfate 15,000 I.U. | Injection | CIPLA BLEOMYCIN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |

13 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Bosentan | Tablet 62.5 mg (as monohydrate) | Oral | Bosentan Cipla | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Calcitriol | Capsule 0.25 microgram | Oral | Calcitriol AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |

14 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Candesartan | Tablet containing candesartan cilexetil 4 mg | Oral | APO‑Candesartan | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Candesartan | Tablet containing candesartan cilexetil 4 mg | Oral | CANDESAN | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Candesartan | Tablet containing candesartan cilexetil 8 mg | Oral | APO‑Candesartan | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |
| Candesartan | Tablet containing candesartan cilexetil 8 mg | Oral | CANDESAN | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |

15 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Calcium | Tablet, chewable, 500 mg (as carbonate) | Oral | Cal‑500 | after 30 November 2023—6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Capecitabine | Tablet 150 mg | Oral | Capecitabine-DRLA | between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand |

16 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Cefaclor | Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL | Oral | APO‑Cefaclor | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Cefaclor | Tablet (sustained release) 375 mg (as monohydrate) | Oral | APO‑Cefaclor CD | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Cefalexin | Capsule 500 mg (as monohydrate) | Oral | APO‑Cephalexin | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Cefazolin | Powder for injection 2 g (as sodium) | Injection | Cefazolin‑AFT | between 1 December 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Cefepime | Powder for injection 1 g (as hydrochloride) | Injection | Cefepime Alphapharm | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Cefepime | Powder for injection 1 g (as hydrochloride) | Injection | Cefepime‑AFT | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Cefepime | Powder for injection 2 g (as hydrochloride) | Injection | Cefepime Alphapharm | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Ceftriaxone | Powder for injection 1 g (as sodium) | Injection | Ceftriaxone‑AFT | between 1 December 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Ceftriaxone | Powder for injection 2 g (as sodium) | Injection | Ceftriaxone‑AFT | between 1 December 2023 and 31 December 2023—0 months stock by reference to usual demand |

17 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Carmellose with glycerin | Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL | Application to the Eye | Optive | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ceftriaxone | Powder for injection 2 g (as sodium) | Injection | Ceftriaxone Viatris | after 31 May 2024—6 months stock by reference to usual demand of both Ceftriaxone Viatris and Ceftriaxone Alphapharm added together |

18 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Citalopram | Tablet 10 mg (as hydrobromide) | Oral | Citalopram AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Citalopram | Tablet 20 mg (as hydrobromide) | Oral | Citalopram AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Citalopram | Tablet 40 mg (as hydrobromide) | Oral | Citalopram AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |

19 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Clarithromycin | Tablet 250 mg | Oral | Clarithromycin AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |

20 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Cyproterone | Tablet containing cyproterone acetate 100 mg | Oral | APO‑Cyproterone | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Cyproterone | Tablet containing cyproterone acetate 100 mg | Oral | Cyprone 100 | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Cyproterone | Tablet containing cyproterone acetate 100 mg | Oral | GenRx Cyproterone Acetate | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Cyproterone | Tablet containing cyproterone acetate 50 mg | Oral | APO‑Cyproterone | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Cyproterone | Tablet containing cyproterone acetate 50 mg | Oral | Cyprone 50 | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Cyproterone | Tablet containing cyproterone acetate 50 mg | Oral | GenRx Cyproterone Acetate | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |

21 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Desvenlafaxine | Tablet (modified release) 100 mg | Oral | Desvenlafaxine Actavis | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Desvenlafaxine | Tablet (modified release) 50 mg | Oral | Desvenlafaxine Actavis | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Dexamethasone with framycetin and gramicidin | Ear drops containing dexamethasone 500 micrograms (as sodium metasulfobenzoate), framycetin sulfate 5 mg and gramicidin 50 micrograms per mL, 8 mL | Application to the Ear | Sofradex | between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand |

22 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Diclofenac | Tablet (enteric coated) containing diclofenac sodium 25 mg | Oral | Diclofenac AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |

23 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Diclofenac | Tablet (enteric coated) containing diclofenac sodium 50 mg | Oral | Diclofenac AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |

24 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Domperidone | Tablet 10 mg | Oral | Motilium | between 1 July 2023 and 31 March 2024—4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Dosulepin | Capsule containing dosulepin hydrochloride 25 mg | Oral | Dosulepin Viatris | after 31 May 2024—6 months stock by reference to usual demand of both Dosulepin Viatris and Dosulepin Mylan added together |

25 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Doxycycline | Tablet 100 mg (as hyclate) | Oral | Doxsig | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Doxycycline | Tablet 100 mg (as monohydrate) | Oral | APO‑Doxycycline | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Doxycycline | Tablet 50 mg (as hyclate) | Oral | APX‑Doxycycline | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |

26 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Doxycycline | Tablet 50 mg (as monohydrate) | Oral | APO‑Doxycycline | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |

27 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Enalapril | Tablet containing enalapril maleate 10 mg | Oral | APO‑Enalapril | 4 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Enalapril | Tablet containing enalapril maleate 10 mg | Oral | Enalapril generichealth | between 1 February 2024 and 31 May 2024—0 months stock by reference to usual demand |

28 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | APO‑Enalapril | 4 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | Enalapril generichealth | between 1 February 2024 and 31 May 2024—0 months stock by reference to usual demand |

29 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Esomeprazole | Capsule (enteric) 20 mg (as magnesium) | Oral | Noxicid Caps | between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand |
| Esomeprazole | Capsule (enteric) 40 mg (as magnesium) | Oral | Noxicid Caps | between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand |
| Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole Apotex | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole Apotex | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |

30 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ezetimibe with simvastatin | Tablet 10 mg‑10 mg | Oral | EZEVYT 10/10 | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑10 mg | Oral | Vytorin | between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑10 mg | Oral | Zeklen 10/10 mg | between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand |

31 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ezetimibe with simvastatin | Tablet 10 mg‑20 mg | Oral | EZEVYT 10/20 | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑20 mg | Oral | Vytorin | between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑20 mg | Oral | Zeklen 10/20 mg | between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand |

32 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ezetimibe with simvastatin | Tablet 10 mg‑40 mg | Oral | EZEVYT 10/40 | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑40 mg | Oral | Vytorin | between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑40 mg | Oral | Zeklen 10/40 mg | between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand |

33 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ezetimibe with simvastatin | Tablet 10 mg‑80 mg | Oral | EZEVYT 10/80 | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑80 mg | Oral | Vytorin | between 1 July 2023 and 31 December 2023—2 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑80 mg | Oral | Zeklen 10/80 mg | between 1 July 2023 and 31 December 2023—1.5 months stock by reference to usual demand |
| Famciclovir | Tablet 125 mg | Oral | Famciclovir‑GA | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Famciclovir | Tablet 250 mg | Oral | Famciclovir‑GA | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Famciclovir | Tablet 500 mg | Oral | Famciclovir‑GA | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |

34 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Flucloxacillin | Capsule 250 mg (as sodium monohydrate) | Oral | APO‑Flucloxacillin | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |

35 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fluorometholone | Eye drops containing fluorometholone acetate 1 mg per mL, 5 mL | Application to the Eye | Flarex | 4 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fluorometholone | Eye drops containing fluorometholone acetate 1 mg per mL, 5 mL | Application to the Eye | Flarex | between 1 February 2024 and 31 July 2024—0 months stock by reference to usual PBS demand |

36 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Furosemide | Tablet 20 mg | Oral | FUROSEMIDE AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Furosemide | Tablet 20 mg | Oral | Urex‑M | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Furosemide | Tablet 40 mg | Oral | FUROSEMIDE AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Furosemide | Tablet 40 mg | Oral | Urex | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Gabapentin | Capsule 100 mg | Oral | Gabapentin APOTEX | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Gabapentin | Capsule 100 mg | Oral | GAPENTIN | between 1 July 2023 and 31 December 2023—3.5 months stock by reference to usual demand |
| Gabapentin | Capsule 300 mg | Oral | Gabapentin APOTEX | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Gabapentin | Capsule 300 mg | Oral | GAPENTIN | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |
| Gabapentin | Capsule 400 mg | Oral | Gabapentin APOTEX | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |

37 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Gabapentin | Tablet 600 mg | Oral | Gabapentin AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |

38 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Gemfibrozil | Tablet 600 mg | Oral | Lipigem | between 1 July 2023 and 31 December 2023—2 months stock by reference to usual demand |

39 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Glimepiride | Tablet 2 mg | Oral | Amaryl | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |

40 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Glimepiride | Tablet 3 mg | Oral | Amaryl | Between 1 October 2023 and 31 December 2023—0 months stock by reference to usual demand |

41 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ibuprofen | Tablet 400 mg | Oral | APO‑Ibuprofen 400 | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |

42 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ipratropium | Nebuliser solution containing ipratropium bromide 250 micrograms (as monohydrate) in 1 mL single dose units, 30 | Inhalation | APO‑Ipratropium | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Ipratropium | Nebuliser solution containing ipratropium bromide 500 micrograms (as monohydrate) in 1 mL single dose units, 30 | Inhalation | APO‑Ipratropium | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Irbesartan with hydrochlorothiazide | Tablet 300 mg‑25 mg | Oral | AVSARTAN HCT 300/25 | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |
| Irbesartan | Tablet 300 mg | Oral | Irbesartan AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Irbesartan | Tablet 75 mg | Oral | Irbesartan AMNEAL | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Irbesartan | Tablet 75 mg | Oral | Irbesartan AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Irinotecan | I.V. injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL | Injection | MEDITAB IRINOTECAN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Irinotecan | I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL | Injection | MEDITAB IRINOTECAN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Isosorbide mononitrate | Tablet 60 mg (sustained release) | Oral | Isosorbide AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Isosorbide mononitrate | Tablet 60 mg (sustained release) | Oral | Monodur 60 mg | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Isotretinoin | Capsule 10 mg | Oral | Rocta 10 | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Isotretinoin | Capsule 20 mg | Oral | Rocta 20 | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Lamotrigine | Tablet 100 mg | Oral | APO‑Lamotrigine | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Lamotrigine | Tablet 200 mg | Oral | APO‑Lamotrigine | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Lamotrigine | Tablet 25 mg | Oral | APO‑Lamotrigine | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Lamotrigine | Tablet 50 mg | Oral | APO‑Lamotrigine | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |

43 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Insect allergen extract‑yellow jacket venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Yellow Jacket Venom | after 30 November 2023—6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Lamivudine with zidovudine | Tablet 150 mg-300 mg | Oral | Lamivudine/Zidovudine Viatris 150/300 | after 31 May 2024—4 months stock by reference to usual demand of both Lamivudine/Zidovudine Viatris 150/300 and Lamivudine 150 mg + Zidovudine 300 mg Alphapharm added together |

44 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Levonorgestrel with ethinylestradiol | Pack containing 21 tablets 150 micrograms‑30 micrograms and 7 inert tablets | Oral | Monofeme 28 | Between 1 October 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Levonorgestrel with ethinylestradiol | Pack containing 21 tablets 150 micrograms‑30 micrograms and 7 inert tablets | Oral | Lenest 30 ED | between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand |

45 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Meloxicam | Capsule 15 mg | Oral | Chem mart Meloxicam | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Meloxicam | Capsule 15 mg | Oral | Terry White Chemists Meloxicam | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Meloxicam | Capsule 7.5 mg | Oral | Chem mart Meloxicam | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Meloxicam | Capsule 7.5 mg | Oral | Terry White Chemists Meloxicam | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Meloxicam | Tablet 7.5 mg | Oral | APX‑Meloxicam | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |

46 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Metformin | Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | Metformin XR 500 APOTEX | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Metformin | Tablet containing metformin hydrochloride 1 g | Oral | APO‑Metformin 1000 | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Metformin | Tablet containing metformin hydrochloride 1 g | Oral | Metformin AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | APO‑Metformin 500 | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | Metformin AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | APO‑Metformin 850 | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | Chem mart Metformin | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | Metformin AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | Terry White Chemists Metformin | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Methotrexate | Solution concentrate for I.V. infusion 1000 mg in 10 mL vial | Injection | Pfizer Australia Pty Ltd | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |

47 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Methoxyflurane | Liquid for inhalation 999 mg per g, 3 ml (with inhaler) | Inhalation by mouth | Penthrox | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Methylprednisolone | Powder for injection 40 mg (as sodium succinate) | Injection | Methylpred | between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand |

48 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Metoclopramide | Injection containing 10 mg metoclopramide hydrochloride (as monohydrate) in 2 mL | Injection | Maxolon | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |

49 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Mirtazapine | Tablet 15 mg (orally disintegrating) | Oral | Mirtazapine AN ODT | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Mirtazapine | Tablet 15 mg | Oral | APO‑Mirtazapine | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Mirtazapine | Tablet 30 mg (orally disintegrating) | Oral | Mirtazapine AN ODT | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Mirtazapine | Tablet 30 mg | Oral | APO‑Mirtazapine | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Mirtazapine | Tablet 30 mg | Oral | Mirtazon | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Mirtazapine | Tablet 45 mg (orally disintegrating) | Oral | Mirtazapine AN ODT | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Mirtazapine | Tablet 45 mg | Oral | APO‑Mirtazapine | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Mirtazapine | Tablet 45 mg | Oral | Mirtazon | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |

50 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Moclobemide | Tablet 150 mg | Oral | APO‑Moclobemide | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Moclobemide | Tablet 150 mg | Oral | Moclobemide AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Moclobemide | Tablet 300 mg | Oral | APO‑Moclobemide | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Moclobemide | Tablet 300 mg | Oral | Moclobemide AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |

51 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Moxonidine | Tablet 200 micrograms | Oral | Moxonidine Viatris | 4 months stock by reference to usual demand of both Moxonidine Viatris and Moxonidine MYL added together |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Moxonidine | Tablet 400 micrograms | Oral | Moxonidine Viatris | 4 months stock by reference to usual demand of both Moxonidine Viatris and Moxonidine MYL added together |
| Mycophenolic acid | Capsule containing mycophenolate mofetil 250 mg | Oral | CellCept | between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand |
| Mycophenolic acid | Tablet containing mycophenolate mofetil 500 mg | Oral | CellCept | between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand |

52 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 10 mg (orally disintegrating) | Oral | APO‑Olanzapine ODT | between 1 July 2023 and 31 December 2023—3.5 months stock by reference to usual demand |
| Olanzapine | Tablet 15 mg (orally disintegrating) | Oral | APO‑Olanzapine ODT | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |

53 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Norfloxacin | Tablet 400 mg | Oral | APO‑Norfloxacin | 2.5 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 10 mg (orally disintegrating) | Oral | Zypine ODT | (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 10 mg, Oral;(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 10 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 10 mg (orally disintegrating), Oral, added together |

54 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 15 mg (orally disintegrating) | Oral | PRYZEX ODT | (a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand(b) after 31 December 2023—3.5 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 15 mg (orally disintegrating) | Oral | Zypine ODT | (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral;(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 15 mg (orally disintegrating), Oral, added together. |
| Olanzapine | Tablet 20 mg (orally disintegrating) | Oral | Zypine ODT | (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral;(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 20 mg (orally disintegrating), Oral, added together |

55 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 5 mg (orally disintegrating) | Oral | Olanzapine ODT generichealth 5 | Between 1 October 2023 and 31 December 2023—0 months stock by reference to usual demand |

56 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 5 mg (orally disintegrating) | Oral | APO‑Olanzapine ODT | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 5 mg (orally disintegrating) | Oral | Zypine ODT | (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral;(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 5 mg (orally disintegrating), Oral, added together |

57 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg | Oral | APX‑Olmesartan/HCTZ | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |

58 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ondansetron | Tablet (orally disintegrating) 4 mg | Oral | APO‑Ondansetron ODT | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Ondansetron | Tablet (orally disintegrating) 4 mg | Oral | Ondansetron AN ODT | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Ondansetron | Tablet (orally disintegrating) 8 mg | Oral | APO‑Ondansetron ODT | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Ondansetron | Tablet (orally disintegrating) 8 mg | Oral | Ondansetron AN ODT | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Ondansetron | Tablet 4 mg (as hydrochloride dihydrate) | Oral | Ondansetron AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Ondansetron | Tablet 4 mg (as hydrochloride dihydrate) | Oral | Ondansetron APOTEX | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Ondansetron | Tablet 8 mg (as hydrochloride dihydrate) | Oral | Ondansetron AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Ondansetron | Tablet 8 mg (as hydrochloride dihydrate) | Oral | Ondansetron APOTEX | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |

59 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Oxycodone | Oral solution containing oxycodone hydrochloride 1 mg per mL, 1 mL | Oral | OxyNorm Liquid 1mg/mL | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Oxycodone | Tablet containing oxycodone hydrochloride 5 mg | Oral | Oxycodone Viatris | after 28 February 2024—6 months stock by reference to usual demand of both Oxycodone Viatris and Oxycodone Mylan added together |

60 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | Pantoprazole APOTEX | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |
| Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | Sozol | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |
| Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Pantoprazole AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Pantoprazole APOTEX | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |

61 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Sozol | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand(b) after 31 December 2023—5.5 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Paraffin with retinol palmitate | Eye ointment, compound, containing liquid paraffin, light liquid paraffin, wool fat, white soft paraffin and retinol palmitate, 5 g | Application to the Eye | VitA-POS | between 1 April 2024 and 30 September 2024—0 months stock by reference to usual demand |

62 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Paroxetine | Tablet 20 mg (as hydrochloride) | Oral | Paroxetine AN | Between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Pegfilgrastim | Injection 6 mg in 0.6 mL single use pre-filled syringe | Injection | Ristempa | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |

63 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Perindopril | Tablet containing perindopril erbumine 4 mg | Oral | Perindopril generichealth | Between 1 October 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Perindopril | Tablet containing perindopril erbumine 8 mg | Oral | Perindopril generichealth | Between 1 October 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Perindopril with amlodipine | Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besilate) | Oral | APO‑Perindopril Arginine/Amlodipine 5/10 | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |

64 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pravastatin | Tablet containing pravastatin sodium 10 mg | Oral | APO‑Pravastatin | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Pravastatin | Tablet containing pravastatin sodium 20 mg | Oral | APO‑Pravastatin | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Pravastatin | Tablet containing pravastatin sodium 40 mg | Oral | APO‑Pravastatin | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Pravastatin | Tablet containing pravastatin sodium 80 mg | Oral | APO‑Pravastatin | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |

65 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pregabalin | Capsule 25 mg | Oral | LYPRALIN | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |

66 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pregabalin | Capsule 300 mg | Oral | LYPRALIN | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |

67 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Probenecid | Tablet 500 mg | Oral | Pro‑Cid | after 30 November 2023—6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Prochlorperazine | Tablet containing prochlorperazine maleate 5 mg | Oral | Stemzine | between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand |

68 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Quetiapine | Tablet 100 mg (as fumarate) | Oral | Quetiapine AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Quetiapine | Tablet 300 mg (as fumarate) | Oral | Quetiapine AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |

69 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | APO‑Rabeprazole | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |
| Raloxifene | Tablet containing raloxifene hydrochloride 60 mg | Oral | APO‑Raloxifene | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |

70 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ramipril | Tablet 2.5 mg | Oral | APO‑Ramipril | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Ramipril | Tablet 5 mg | Oral | Prilace | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |

71 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ramipril | Capsule 1.25 mg | Oral | APO‑Ramipril | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |

72 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Risperidone | Tablet 1 mg | Oral | APO‑Risperidone | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |

73 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Risperidone | Tablet 4 mg | Oral | Rispa | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |
| Rizatriptan | Tablet (orally disintegrating) 10 mg (as benzoate) | Oral | Rizatriptan AN ODT | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Rosuvastatin | Tablet 10 mg (as calcium) | Oral | APX‑Rosuvastatin | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Rosuvastatin | Tablet 5 mg (as calcium) | Oral | APX‑Rosuvastatin | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Rosuvastatin | Tablet 5 mg (as calcium) | Oral | Crosuva 5 | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |

74 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Risperidone | Tablet 3 mg | Oral | Risperidone generichealth | between 1 November 2023 and 31 March 2024—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Risperidone | Tablet 4 mg | Oral | Risperidone generichealth | between 1 February 2024 and 30 April 2024—0 months stock by reference to usual demand |

75 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Salbutamol | Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30 | Inhalation | Salbutamol AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |

76 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Sertraline | Tablet 100 mg (as hydrochloride) | Oral | Sertraline AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Sertraline | Tablet 50 mg (as hydrochloride) | Oral | Sertraline AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Sildenafil | Tablet 20 mg (as citrate) | Oral | Sildenafil AN PHT 20 | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |

77 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Sotalol | Tablet containing sotalol hydrochloride 160 mg | Oral | APO‑Sotalol | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |

78 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Sotalol | Tablet containing sotalol hydrochloride 80 mg | Oral | APO‑Sotalol | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |

79 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Tacrolimus | Capsule 0.5 mg | Oral | Tacrograf | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |

80 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Temozolomide | Capsule 180 mg | Oral | Temodal | between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Temozolomide | Capsule 250 mg | Oral | Temodal | between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand |

81 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral | Tenofovir/Emtricitabine 300/200 APOTEX | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg | Oral | Tenofovir Disoproxil Emtricitabine Viatris 300/200 | after 30 April 2024—4 months stock by reference to usual demand of both Tenofovir Disoproxil Emtricitabine Viatris 300/200 and Tenofovir Disoproxil Emtricitabine Mylan 300/200 added together |

82 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Triglycerides, medium chain | Oral liquid 225 mL, 15 (K.Quik) | Oral | K.Quik | 0 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Trimethoprim | Tablet 300 mg | Oral | Trimethoprim Viatris | after 30 April 2024—6 months stock by reference to usual demand of both Trimethoprim Viatris and Trimethoprim Mylan added together |
| Tropisetron | I.V. injection 5 mg (as hydrochloride) in 5 mL | Injection | Tropisetron-AFT | between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand |

83 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Voriconazole | Powder for oral suspension 40 mg per mL, 70 mL | Oral | Vfend | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Voriconazole | Tablet 200 mg | Oral | Vfend | between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand |

84 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ziprasidone | Capsule 20 mg (as hydrochloride) | Oral | APO‑Ziprasidone | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Ziprasidone | Capsule 40 mg (as hydrochloride) | Oral | APO‑Ziprasidone | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Ziprasidone | Capsule 60 mg (as hydrochloride) | Oral | APO‑Ziprasidone | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Ziprasidone | Capsule 80 mg (as hydrochloride) | Oral | APO‑Ziprasidone | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |

Schedule 2—Amendments commencing 1 June 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Chloramphenicol | Eye drops 5 mg per mL, 10 mL | Application to the Eye | Chlorsig | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Chlorpromazine | Injection containing chlorpromazine hydrochloride 50 mg in 2 mL | Injection | Largactil | 6 months stock by reference to usual PBS demand |
| Chlorpromazine | Oral solution containing chlorpromazine hydrochloride 25 mg per 5 mL, 100 mL | Oral | Largactil | 6 months stock by reference to usual PBS demand |
| Chlorpromazine | Tablet containing chlorpromazine hydrochloride 100 mg | Oral | Largactil | 6 months stock by reference to usual PBS demand |

2 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Chlorpromazine | Tablet containing chlorpromazine hydrochloride 25 mg | Oral | Largactil | 4 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Chlorpromazine | Tablet containing chlorpromazine hydrochloride 25 mg | Oral | Largactil | 6 months stock by reference to usual PBS demand |

3 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Paraffin with retinol palmitate | Eye ointment, compound, containing liquid paraffin, light liquid paraffin, wool fat, white soft paraffin and retinol palmitate, 5 g | Application to the Eye | VitA-POS | between 1 April 2024 and 30 September 2024—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Periciazine | Tablet 10 mg | Oral | Neulactil | 6 months stock by reference to usual PBS demand |

4 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Periciazine | Tablet 2.5 mg | Oral | Neulactil | 4 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Periciazine | Tablet 2.5 mg | Oral | Neulactil | 6 months stock by reference to usual PBS demand |